HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ICRF 159 plus radiation versus radiation therapy alone in cervical carcinoma. A double-blind study.

Abstract
In a double-blind trial the effect of ICRF 159 or placebo associated with radiotherapy was compared in 70 patients with cervical carcinoma. No significant differences were found on histopathological examination of surgical specimens obtained 6 weeks after the end of the treatment. Clinical evaluation after a follow-up of 46 +/- 5 months, also showed no significant effect of ICRF 159 with radiotherapy.
AuthorsC Belloni, C Mangioni, G Bortolozzi, S Carinelli, M D'Incalci, A Maggioni, L Morasca
JournalOncology (Oncology) Vol. 40 Issue 3 Pg. 181-5 ( 1983) ISSN: 0030-2414 [Print] Switzerland
PMID6341912 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Piperazines
  • Placebos
  • Razoxane
Topics
  • Carcinoma, Squamous Cell (drug therapy, radiotherapy)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Neoplasm Staging
  • Piperazines (therapeutic use)
  • Placebos
  • Razoxane (adverse effects, therapeutic use)
  • Uterine Cervical Neoplasms (drug therapy, radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: